Since physiological agonists, such as VIP, signal through multiple pathways, for example, by elevating both cAMP and Ca2+, clustering and platform-dependent stabilization are likely to enhance the efficacy of CF corrector drugs (Langer, 2012; Abu-Arish et al., 2019). This evidence concerns the gene VIP and cystic fibrosis.